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Abstract: Prevention and correction of hyperphosphatemia is a major goal of chronic kidney 
disease–mineral and bone disorder (CKD–MBD) management, achievable through avoidance 
of a positive phosphate balance. To this aim, optimal dialysis removal, careful use of phosphate 
binders, and dietary phosphate control are needed to optimize the control of phosphate balance 
in well-nourished patients on a standard three-times-a-week hemodialysis schedule. Using a 
mixed diffusive–convective hemodialysis tecniques, and increasing the number and/or the dura-
tion of dialysis tecniques are all measures able to enhance phosphorus (P) mass removal through 
dialysis. However, dialytic removal does not equal the high P intake linked to the high dietary 
protein requirement of dialysis patients; hence, the use of intestinal P binders is mandatory to 
reduce P net intestinal absorption. Unfortunately, even a large dose of P binders is able to bind 
approximately 200–300 mg of P on a daily basis, so it is evident that their efficacy is limited 
in the case of an uncontrolled dietary P load. Hence, limitation of dietary P intake is needed to 
reach the goal of neutral phosphate balance in dialysis, coupled to an adequate protein intake. 
To this aim, patients should be informed and educated to avoid foods that are naturally rich in 
phosphate and also processed food with P-containing preservatives. In addition, patients should 
preferentially choose food with a low P-to-protein ratio. For example, patients could choose 
egg white or protein from a vegetable source. Finally, boiling should be the preferred cooking 
procedure, because it induces food demineralization, including phosphate loss. The integrated 
approach outlined in this article should be actively adapted as a therapeutic alliance by clinicians, 
dieticians, and patients for an effective control of phosphate balance in dialysis patients.
Keywords: phosphorus, hyperphosphatemia, dialysis, phosphate binders, diet, food 
preservatives
Introduction
Phosphorus (P; atomic weight 31 Daltons) is a mineral widely present in nature as 
phosphate. In humans, it plays an essential role in bone metabolism, cellular signal-
ing, nucleous, and energy metabolism. About 80%–85% of the total body P is found 
in bones and teeth as calcium salts; about 15%–20% is present in body fluids and soft 
tissues. It is noteworthy that circulating P levels, ie, the fraction measurable in clinical 
practice, represents only 0.1% of total body P.
In the course of chronic kidney disease (CKD), P serum levels remain within nor-
mal limits until the advanced stages of CKD. Therefore, hyperphosphatemia must be 
considered a very late indicator of P retention.1 Instead, the increase of P serum levels 
in the individual patient, even within the normal range, may occur quite early in the 
course of CKD (as little as 50 mL/minute of glomerular filtration rate), accompanied by 
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the increase in PTH (parathyroid hormone) and even earlier 
by the increase of FGF23 (fibroblastic growth factor 23).1 
Following a  dietary intake of P, from the very early stages of 
CKD, FGF23 causes a phosphaturic response contributing to 
maintenance of a neutral P balance.
An increase in the risk of cardiovascular morbidity and 
mortality due to chronic hyperphosphatemia in patients under-
going hemodialysis has been demonstrated.2 Numerous stud-
ies published in the field since the late 1980s have underpinned 
a drastic shift in the focus of nephrologists from bone damage 
and extravascular calcification of the soft tissues, particularly 
periarticular and ocular disorders in uremic patients,3 to the 
cardiovascular damage related to Ca–P metabolism abnor-
malities.4 This new aspect has led to a redefinition of the term 
“uremic osteodystrophy” to include a more comprehensive 
definition, namely chronic kidney disease–mineral and bone 
disorder (CKD–MBD). The main target of pharmacologi-
cal research in the field has also moved from bone toward 
the cardiovascular apparatus. Prevention and correction 
of hyperphosphatemia is a major goal of the treatment of 
CKD–MBD, so special attention must be given to P balance. 
Phosphate enters the body by intestinal absorption of dietary 
P; it is excreted through stools and dialysis fluids (plus urine 
output in patients with residual renal function). In the case 
of daily dialysis or long nocturnal dialysis, P mass removal 
is usually large enough to reduce the need of dietary restric-
tions and the use of P binders. This does not occur in the case 
of well-nourished patients on a standard three-times-a-week 
dialysis schedule where optimal dialysis removal, careful 
use of phosphate binders, and dietary P control are needed 
to optimize the control of P balance.
Dialysis
Despite the recent revolutionary advances in dialysis technol-
ogy and the improved quality of membranes, the challenge 
represented by P removal continues at an uneven pace when 
adopting conventional depuration techniques, even in the 
presence of high-flux convective exchanges.
Several key concepts should be kept in mind regarding 
dialytic removal of P. The intradialytic output kinetics of P are 
completely different from that of urea or other small molecules 
for the different body volume distributions. Furthermore, mass 
transfer of P is hindered because this molecule, albeit of a 
low molecular weight, is coated with water particles that bind 
strongly to P, thus transforming an originally small molecule 
into a molecule of medium dimension. Thus, its increased 
hydrated radius renders the passage through the pores of the 
dialysis membrane more difficult. Few investigations5,6 have 
been carried out on the structure and dynamics of hydrogen 
bonds between the H
2
PO
4
−, HPO
4
2−, and PO
4
3−. Experimental 
data have been published on the hydration of P ions employ-
ing different techniques for the purpose of investigating the 
ion and its surroundings; moreover, the P-oxyanion features 
a higher charge (3−),5,6 further slowing the passage through 
the dialysis membrane. It is noteworthy that the three forms 
of P ions are approximately spherical, with an average van 
der Waals radius of more than 180 Å.
Almost all studies addressing P mass transfer are poten-
tially affected by different biases. In fact, the majority of inves-
tigations used routine colorimetric techniques for determining 
P levels in plasma that are not highly accurate, particularly due 
to the use of strong acids in routine laboratory procedures to 
determine the phosphomolybdate complex.7,8 These strong 
acids, although in contact with the plasma only very briefly, 
produce an immediate breakdown of proteins in plasma and/or 
serum with P release and overestimation of its actual levels.9
The multicompartmental distribution of P and its slow 
shift from the intracellular to the extracellular compartment 
and to plasma, render the postdialysis P rebound complex 
and difficult to define in terms of quantity and duration.9,10 
Likewise, it is not an easy task to identify the most appro-
priate time for sampling, with the aim of establishing a sort 
of time-average P concentration. Undoubtedly, predialysis 
sampling following the long interdialysis interval is the least 
favorable time for assessing dietary and therapeutic compli-
ance and for establishing a tailored-dose regimen and type 
of intestinal P binder. The timing of the serum P assessment 
may also influence the use of vitamin D and its derivatives. 
Moreover, the same predialytic levels of P in different con-
ditions of acidosis make the establishment of its real mass 
transfer more difficult. Recently, physical exercise has been 
implemented during hemodialysis in an attempt to increase 
the removal of several molecules, including P.11
In Table 1, ranges of weekly P removals are reported for 
the different extracorporeal techniques.
Table 1 Ranges of phosphate removal (grams per week) by 
different dialysis strategies
Conventional diffusive hemodialysis, 4 hours 2.3–2.6 g
extended diffusive hemodialysis, $5 hours 3.0–3.6 g
Nocturnal hemodialysis, ∼8 hours 4.5–4.9 g
Endogenous hemofiltration with reinfusion, 4 hours 1.8–2.4 g
Postdilution hemodiafiltration, 4 hours 3.0–3.3 g
Predilution hemofiltration (exchange volumes  
1.2 × body weight)
 
0.9–1.5 g
Peritoneal dialysis (CAPD, 2 L × 4/day) 2.0–2.2 g
Abbreviation: CAPD, continuous ambulatory peritoneal dialysis.
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Diffusive hemodialysis techniques
In view of the large mass of P requiring removal, diffusion 
of P is insufficient both with high-efficiency membranes or 
with standard membranes with a low ultrafiltration coef-
ficient, when dialysis is scheduled according to the conven-
tional three-times-a-week regimen. Determination of the 
amount of P excreted through the different diffusive  dialysis 
techniques is not an easy task. A series of variables may be 
present: patient predialysis P levels; membrane surface and 
permeability characteristics; session duration – currently one 
of the most relevant factors. With the traditional diffusive 
dialysis regimen (three sessions per week), P removal is 
highly variable (Table 1).12 Thus, in a patient consuming a 
normal protein diet of 1.2 g/kg/day, the need for intestinal P 
binders is mandatory, and it is of the utmost importance to 
ensure that they are taken regularly as prescribed. However, 
in some hemodialysis patients – independently of food intake 
and of vitamin D status – P levels within the normal range, 
accompanied by normal calcium and PTH levels, may be 
detected.13 This phenomenon may be due to: malfunctioning 
of the intestinal absorptive carrier; and/or to malabsorption 
phenomena; and/or nutritional disorders, often of a heredi-
tary nature.
Even in the case of noncompliant patients, excellent 
results can be achieved through implementation of specific 
dialysis regimens. Indeed, numerous studies have demon-
strated how daily14 or nocturnal dialysis15 results in an optimal 
control of P levels, at times requiring P supplementation to 
achieve normal values,16,17 or at least leading to a reduction 
in the use of chelating agents. The risk involved is compa-
rable to that of the refeeding syndrome, producing an effect 
on blood counts and neuromuscular apparatus, which – in 
chronic forms – may lead to the subtle and gradual onset of 
damage.18 A review of the literature confirms that the most 
suitable means of controlling hyperphosphatemia is time-
related, indirectly demonstrating that the characteristics of 
P removal in dialysis resemble those of a medium-sized 
molecule.
Convective hemodialysis techniques
Predilution hemofiltration (HF) has fallen short of expecta-
tions with regard to P removal, even in the presence of optimal 
levels of adequacy. In convective methods, the latter is not 
defined on the basis of Kt/V, but it is quantified by exchange 
volumes capable of reaching, albeit with difficulty, 1.2 times 
the body weight of the patient.
A comparison carried out between HF and hemodiafil-
tration (HDF), at times accompanied by ultrafiltration of 
similar volumes to that of urea distribution, results in the 
gradual discontinuation of online HF procedures. Although 
these studies were designed to evaluate outcomes of arterial 
blood pressure and intrasession symptoms, no differences 
were observed in presession P levels, and no superiority of 
HF compared to HDF was observed.19,20 Since the end of 
the 1990s, a new hemodialytic method was introduced that 
employed three types of depuration: convection; adsorption 
by resins; and diffusion.21 An ultrafiltrate is formed by the 
plasma water leaving the convective filter, and it is conveyed 
into a cartridge containing adsorbents (polystyrenic resin), 
which retain various high molecular-weight toxic substances. 
In the last step, the further purified plasma water goes into 
the diffusive filter. This technique, called “HFR” (HDF with 
endogenous reabsorption), allows the saving of useful sub-
stances (eg, vitamins) and adsorption of several cytokines. It 
is the only HDF that can be defined by the term “endogenous.” 
The possibility of a favorable effect on CKD–MBD because 
of higher P depuration by ultrafiltration and adsorption was 
considered. HFR confirmed its high rate of elimination of 
cytokines but only a modest adsorption of P.9 Nevertheless, 
this study revealed chemical titration as the gold standard 
for the determination of P kinetics. The common chemical–
clinical laboratory equipment, using strong acids such as 
sulfuric acid, produces a rapid breakdown of proteins. This 
accurate method of titration provides a deproteinized plasma 
with a weak acid (10% trichloroacetic acid in aqueous solu-
tion), preventing breakdown of the proteins and, therefore, 
releasing ultrafilterable P. Subsequently, the supernatant was 
drawn, in which the P ion was made to react with a solution 
of ammonium molybdate with formation of a phosphomo-
lybdic complex reduced to molybdenum blue with stannous 
chloride. The P concentration was obtained by means of a 
calibration curve plotted, starting from the standard. The 
same method was used for the dialysis fluid samples, omit-
ting the deproteinization phase. Generally, HDF techniques 
show middle molecule higher removal capacity per session 
than diffusive procedures. These observations have been 
demonstrated for postdilution,22 predilution, prepostdilution, 
and reverse middilution methods.23 Studies aimed at inves-
tigating P mass transfer using the above methods are scarce, 
focusing almost entirely on the control of predialysis P levels. 
It is mandatory, however, that a congruous reinfusion dose 
be used, ie, higher than 18–20 L per session in postdilution 
HDF. Subsequent studies demonstrated a decrease in mor-
tality and better survival rates, which could be attributed, at 
least in part, to an improved control of hyperphosphatemia 
and/or of secondary hyperparathyroidism.24–26 In pre- and 
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postdilution HDF, removal efficiency is highly dependent 
on the exchange volume of plasma water/ultrafiltrate, which 
should be similar to urea distribution, corresponding to the 
percentage of total body water (approximately 58%–60%, 
according to subject’s age).27 HDF is capable of achieving 
removal rates exceeding 4–5 g/week,12 significantly higher 
than levels yielded by diffusion methods. It may be useful 
to consider the filtration fraction (FF), which is the ratio 
between ultrafiltration flow rate divided by plasma water 
flow rate (Q
UF
/Q
pwin
), to estimate the share of the larger 
molecule ultrafiltration output. The exact proportion is not 
well determined for the various types of HDF, but it can be 
estimated as follows: 0.5 (ultrafiltration [UF] rate = 30% 
of Q
b
) for HDF-post; 0.7–1.25 (UF rate = 50%–70% of Q
b
) 
for HDF pre- and HDF pre-post; and $1.5 (UF rate = 100% 
of Q
b
) for HF predilution.28–30 However, the “gold standard” 
for HDF for P clearance needs further studies to be identified 
convincingly. Today, the total time spent in dialysis is consid-
ered one of the strongest factors that influence P levels. This 
finding supports the use of mixed methods in daily dialysis 
by means of HDF.31 In fact, when daily dialysis is carried out 
with high-convection methods, it is possible to obtain further 
progress, but studies about daily HDF and/or daily HF are 
rare and not significant.
Peritoneal dialysis
In terms of efficacy and providing a high level of support to 
the peritoneum, peritoneal dialysis may be viewed as a form 
of long-term dialysis, combining the advantages of a better 
quality of life, particularly when using automated methods, 
with significantly lower costs.
The yield of P removal by peritoneal dialysis, particu-
larly in anuric patients, is indicated as a highly important 
reference parameter. P clearance may reach 40 L/week per 
1.73 m2, similar to levels obtained for creatinine clearance. 
In this condition, the presence of phosphaturia in patients 
with preserved urine output plays a positive role. Total 
P removal is strongly correlated with residual renal function 
parameters, but it is dissociated from peritoneal Kt/V urea 
and creatinine clearance. No correlation between P clear-
ance and net ultrafiltration has been demonstrated. Renal 
and peritoneal P clearance rates were significantly lower in 
hyperphosphatemic patients. Slow transporters presented 
higher peritoneal P clearance under continuous ambulatory 
peritoneal dialysis (CAPD) regimens. Hyperphosphatemia 
has been significantly associated with a lower number of 
automated peritoneal dialysis (APD) cycles and a shorter 
duration of nocturnal treatment, with insufficient dwell time.32 
In hyperphosphatemic and/or anuric patients, the decision 
to implement peritoneal dialysis should take into account 
peritoneal P transport characteristics and not be based solely 
on urea Kt/V or peritoneal creatinine clearance. Increasing 
dwell times or transfer to CAPD may represent effective 
strategies aimed at improving P management in patients with 
inadequate P control on APD. Interesting considerations on 
a more optimal purification of P by peritoneal dialysis have 
been proposed recently and need further study,33 but if we 
consider a very efficient peritoneal membrane and adequate 
dwell time, as it happens with nocturnal APD, patients on 
peritoneal dialysis might achieve a better P control.
Intestinal phosphate binders
Intestinal P binders are frequently administrated to control 
serum P levels in CKD patients, since dialysis removal and 
dietary restriction are often not sufficient to reach an adequate 
control of hyperphosphatemia.
Several P binders are available, acting with different 
mechanisms. They can be classified, according to their chemi-
cal properties as aluminum-based binders, calcium-based 
binders, or aluminum- and calcium-free binders. The main 
features of P binders commonly used in clinical practice are 
depicted in Table 2.
Aluminum-based binders
Aluminum-based binders have been largely used to control 
hyperphosphatemia in the past. Although very effective, 
their long-term use is not recommended by Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines because of 
significant adverse events. In fact, aluminum accumulation 
has been demonstrated in bone and cerebral tissues, result-
ing in toxicity, known as aluminum-induced osteomalacia 
and encephalopathy.34,35 Moreover, a safe aluminum dose 
is not known for the individual patient. For these reasons, 
aluminum binders have been replaced by calcium-based 
and calcium-free binders, although in some countries they 
are still used in a significant number of patients. In a cross-
sectional study conducted between 2002–2007 in peritoneal 
dialysis patients, data on P binders’ use were obtained from 
369 patients.36 Among the 327 patients (88.6%) receiving P 
binders, combination treatment was very common: 49% of 
patients received calcium carbonate; 35.5% sevelamer; 29.5% 
magnesium-containing binders; and 31.4%, surprisingly, 
aluminum-based binders. Although the most severe cases of 
aluminum toxicity in the past were caused by poorly treated 
water in the dialysis fluid, intestinal absorption of aluminum 
has been proved and in specific categories (anuric patients, 
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children, and patient concomitantly assuming citrate, even 
unconsciously) it can cause adverse symptoms and even 
death.37
Calcium-based phosphate binders
Introduced in the 1980s and widely prescribed, calcium salts 
are known as effective and well-tolerated intestinal P binders. 
They are available in different formulations: calcium carbon-
ate; calcium acetate; and calcium citrate. The latter is not used 
in dialysis patients, because citrate can facilitate intestinal 
absorption of aluminum.34
Calcium acetate, which shows the same relative P binder 
coefficient as calcium carbonate,38 achieves control of hyper-
phosphatemia with the same efficacy, but with a lower dose 
of elemental calcium.39
Current guidelines suggest prescribing calcium-based 
binders with caution, avoiding high dosage, and paying 
attention to their adverse effects. In particular, calcium 
binders may induce a positive calcium balance, leading to 
PTH oversuppression, adynamic bone disease, and vascular 
calcifications by calcium deposition in vessels and tissues. 
Moreover, it has been suggested that differences in mortal-
ity may be associated with the use of calcium-based binders 
when compared to sevelamer, considering the potential role of 
coronary and aortic calcifications as predictors of mortality. 
Studies addressing the compared effects of calcium-based 
binders and sevelamer are discussed below, in the sevelamer 
section of this article.
The issue of the effect of calcium-based binders on 
mortality in hemodialysis patients was addressed in a large 
observational study.40 In a study on 3,603 incident dialysis 
patients, 77.5% used a calcium-based binder, while 22.5% 
did not. Baseline use of calcium-based binders was associ-
ated with an adjusted 19% lower mortality rate compared 
Table 2 Phosphate binders in hemodialysis patients: a summary of their main features, advantages, and adverse events
Chemical composition RPBC Advantages Adverse events/ 
disadvantages
Aluminum hydroxide 
Aluminum carbonate
Aluminum 1.5 
1.7
very effective; inexpensive encephalopathy; adynamic  
bone disease; anemia; proximal  
myopathy
Calcium carbonate Calcium carbonate,  
500 mg (elemental calcium,  
40%, 200 mg)
1 effective; inexpensive Gastrointestinal complications,  
20% (nausea, vomiting,  
diarrhea, constipation);  
hypercalcemia, 16%; vascular  
calcifications
Calcium acetate (Phoslo) Calcium acetate, 667 mg  
(elemental calcium, 25%,  
169 mg)
1 effective; inexpensive Gastrointestinal complications,  
20% (nausea, vomiting,  
diarrhea, constipation);  
hypercalcemia, 17%; vascular  
calcifications
Calcium acetate/ 
magnesium carbonate  
(Osvaren)
Calcium acetate, 435 mg/ 
magnesium carbonate, 235 mg  
(elemental calcium, 110 mg)
1/1.3 effective; less hypercalcemia  
than other calcium binders; 
prevention of vascular  
calcifications
Gastrointestinal complications  
(nausea, diarrhea, 3.6%);  
muscle spasms (1.7%);  
hypermagnesemia (2.1%)
Sevelamer hydrochloride 
(Renagel)
Anion-exchange resin, 800 mg 0.75 effective; nonclassical  
effects (reduces cholesterol  
and uric acid, anti- 
inflammatory action)
Gastrointestinal complications:  
30% (nausea, vomiting,  
diarrhea, constipation); etabolic 
acidosis; expensive
Sevelamer carbonate  
(Renvela)
Anion-exchange resin, 
800/2,400 mg
0.75 effective; absence/low risk  
of metabolic acidosis versus  
sevelamer HCl
Gastrointestinal complications  
less than sevelamer HCl:  
20% (nausea, vomiting,  
diarrhea, constipation);  
expensive
Lanthanum carbonate 
(Fosrenol or Foznol)
Lanthanum,  
250/500/750/1,000 mg
2 effective; no evidence of  
bone toxicity; improved  
compliance by fewer daily  
tablets
Gastrointestinal events:  
10% (nausea, vomiting,  
diarrhea, constipation); rarely 
headache, dizziness,  
hypotension, myalgia; expensive
Notes: Frequencies of the most common side effects have been reported in percentage of affected patients, based on the available data in published controlled studies. Data 
for RPBC from38.
Abbreviation: RPBC, Relative Phosphate-Binding Coefficient.
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with nonusers. However, matching 800 exposed and 
nonexposed individuals on their exposure propensity score, 
calcium users and nonusers had similar mortality rates. No 
mortality differences were observed between calcium acetate 
and calcium carbonate users in crude, adjusted, or propensity-
matched analyses.40
A more recent calcium-based formulation comprises 
calcium acetate and magnesium carbonate (CaMg). In a 
randomized controlled study comparing CaMg and calcium 
carbonate, lower P and calcium levels were observed in 
the group of patients treated with CaMg.41 CaMg allowed 
a decrease in calcium daily intake and the avoidance of 
hypercalcemia; an increase of magnesium serum level was 
observed in patients treated with CaMg, but apparently with-
out a clinical impact. In the CALcium acetate MAGnesium 
carbonate evaluation (CALMAG) study, addressing P control 
in 244 hemodialysis patients followed for 24 weeks, CaMg 
results were not inferior to sevelamer HCl, without changes 
in ionized calcium, minimal increase of serum calcium and 
magnesium, and a good tolerability.42 An interesting feature 
of magnesium is its inhibiting effect on vascular calcifica-
tions in in-vitro and experimental models.43 Some authors 
observed a significant association between low serum mag-
nesium levels and vascular calcifications in 390 hemodialysis 
patients.44 The role of possible magnesium accumulation in 
bone tissues is still uncertain.
Sevelamer hydrochloride  
or carbonate
Sevelamer hydrochloride (HCl) is an anion-exchange resin, 
and it is the most commonly used calcium and aluminum-
free P binder. The efficacy of this binder in reducing P lev-
els is well established.45 Sevelamer can reduce the impact 
of calcium overload in dialysis patients, also allowing 
prevention of cardiovascular complications by its nonclas-
sical pleiotropic effects.46
In the Treat to Goal Study,47 administration of sevelamer 
HCl was associated with a reduction in the progression of 
coronary calcification, compared with the administration of 
calcium-based binders. Calcium salts also caused more epi-
sodes of hypercalcemia.47 These results were not confirmed 
by the Calcium Acetate (PhosLo®)/Sevelamer (Renagel®) 
Evaluation Study 2 (CARE-2) study, which also compared 
the use of calcium acetate and sevelamer in the hemodialysis 
population.48 In this study, cardiovascular calcifications pro-
gressed similarly but significantly in both treatment groups, 
suggesting differences in the patient population or in the 
experimental design, compared to the Treat to Goal study.
In the Renagel in New Dialysis (RIND) Study,49 which 
enrolled patients new to dialysis, use of calcium-containing P 
binders resulted in more rapid progression of coronary cal-
cification than did the use of sevelamer HCl in subjects with 
evidence of at least mild coronary calcification. However, 
new hemodialysis patients with no evidence of coronary cal-
cification did not develop new calcifications over 18 months, 
independent of P binder therapy.49
A 44-month follow-up study assessed all-cause mortality 
in 127 patients of the RIND study.50 Baseline coronary calci-
fications were a significant predictor of mortality. Mortality 
was borderline significantly lower in subjects randomized to 
sevelamer (5.3/100 patient-years) compared to those random-
ized to calcium-containing binders (10.6/100 patient-years).50 
With the aim of confirming such relevant mortality data, a large 
randomized trial compared sevelamer and calcium-based bind-
ers on all-cause and cause-specific mortality (cardiovascular, 
infection, and other) in 2,103 prevalent hemodialysis patients.51 
Overall, all-cause mortality rates and cause-specific mortality 
rates were not significantly different, but in a prespecified set of 
patients over 65 years of age, there was a significant effect of 
sevelamer in lowering the mortality rate.51 Hospitalization rates 
were a secondary outcome of the Dialysis Clinical Outcomes 
Revisited (DCOR) study. Multiple all-cause hospitalization 
rate (1.7 versus 1.9 admissions/patient-year) and hospital 
days (12.3 versus 13.9 days/patient-year) were lower in the 
sevelamer group.52
Sevelamer has pleiotropic or nonclassical effects, such 
as reduction of lipid serum levels and anti-inflammation 
activity,53 which are attractive characteristics when consid-
ering the primary drug of choice for the control of hyper-
phosphatemia, despite their higher cost. On the other hand, 
a reduced bicarbonate level can be observed when switching 
a patient from calcium carbonate to sevelamer HCl;54 pill 
burden is relevant; and poor compliance for intestinal adverse 
effects has been observed.
Few data about the use of calcium-based and calcium-
free P binders are available in peritoneal dialysis patients.36,55 
In a multicenter and open-label study conducted in 143 peri-
toneal dialysis patients, calcium acetate and sevelamer 
had the same efficacy and similar tolerability, but they 
increased serum calcium levels in calcium acetate-treated 
patients.56
Sevelamer carbonate is a new formulation of sevelamer. 
Like sevelamer HCl, it is an anion exchange resin, where car-
bonate replaces chloride. It is as effective as sevelamer HCl, 
but it is able to better control the acid-base status, showing 
less incidence of metabolic acidosis; and it is better tolerated 
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than sevelamer HCl, especially for a reduced incidence of 
gastrointestinal effects.57 Sevelamer carbonate is available in 
two formulations – tablets and powder. Powder formulation 
may be helpful for the elderly and pediatric populations 
because of easier administration, but they also contribute 
to improve compliance because of the higher drug content 
(2,400 mg), compared to the 800 mg tablet.
Lanthanum carbonate
Lanthanum carbonate (LC) is another noncalcium, non-
aluminum P binder, available in tablets and in a recently 
released oral powder formulation. Lanthanum is a trivalent 
metal, similar to aluminum. Its absorption is minimal in the 
intestine, but it is excreted by the liver rather than the kidney 
which minimizes its potential toxicity. Its ability to reduce P 
levels is similar to aluminum hydroxide and two times higher 
than calcium carbonate.58 Its presence within the intestine 
can determine multiple radiopaque images in abdominal 
X-rays. Gastrointestinal adverse events are reported as the 
main side effects.59
A randomized study conducted in hemodialysis popula-
tions reported good 2-year tolerability and efficacy of LC, 
with less incidence of hypercalcemia and improved control 
of PTH levels in the group of patients treated with LC, 
compared with patients treated with calcium binders.60 The 
efficacy of LC in the peritoneal dialysis population is similar 
to hemodialysis.61 In a more recent study,62 high doses of 
LC (2,250 mg/day) were effective in P control in 39 CAPD 
patients, leading the authors to suggest the possibility of 
improving nutrition and protein intake without compromis-
ing serum P control.62
However, long-term data on safety are still scarce, 
suggesting that patients treated with LC should be moni-
tored carefully. Up to now, no evidence of bone toxicity is 
reported. In particular, in a multicenter randomized study 
conducted to evaluate the safety and efficacy of LC on bone 
disease, 49 patients were randomized to receive LC, and 
49 patients received calcium carbonate. LC-treated dialysis 
patients showed no evolution to bone disease and no associa-
tion with aluminum bone toxicity.63 These results were also 
confirmed by other authors, showing that bone deposition after 
1 year of treatment with LC was low, while a slow release of 
LC was observed after 2 years of follow-up, without evidence 
of osteomalacia or any forms of bone toxicity.64
Miscellanea
Despite the widespread use of P binders, some patients do 
not achieve the target of adequate P levels. Limitations and 
side effects of traditional binders have led to the development 
of novel therapeutic strategies.
Chitosan chewing gum
In consideration of the elevated salivary P levels in dialysis 
patients,65 it was found that the use of a salivary P-binding 
chewing gum – in addition to conventional binders – could 
improve the management of hyperphosphatemia in patients 
resistant to traditional therapy.66
Iron-based binders
The role of iron-based binders derives from the observations 
in uremic and nonuremic rats that iron salts and complex 
compound (crosslinked dextran and stabilized polynuclear 
iron hydroxide) reduced urinary excretion of P, suggesting 
a decreased intestinal P uptake.67 In a short-term study con-
ducted in a small group of hemodialysis patients, the use 
of PA21 (stabilized polynuclear iron [III]-oxyhydroxide), 
already known for its ability to bind to iron in in-vitro study, 
was well-tolerated and associated with a reduction of P serum 
levels.68 Other long-term and controlled studies are necessary, 
but these preliminary results suggest an alternative strategy to 
treat hyperphosphatemia. Gastrointestinal side effects should 
be evaluated in larger studies.
Colestilan
This nonmetallic and noncalcium P binder acts as an 
anion exchange resin, and it is not absorbed after oral 
administration. Preliminary studies have demonstrated its 
capability to bind dietary P within the intestinal tract. It 
can also bind bile acids, reducing low-density lipoprotein 
(LDL) serum levels. In a recent placebo-controlled study, the 
efficacy of fixed doses of colestilan (3, 6, 9, 12, or 15 g/day) 
were compared to placebo for the control of serum P in 
642 dialysis patients. Colestilan was most effective at the 
dose of 9 g/day after 12 weeks of therapy, without increasing 
calcium serum levels. The most common adverse events were 
gastrointestinal (nausea, vomiting).69
Nicotinamide
This is an inhibitor of sodium-dependent P cotransport in the 
small intestine.70,71 For these properties, it has been proposed 
as an alternative binder for controlling hyperphosphatemia 
and hyperparathyroidism without inducing hypercalcemia in 
hemodialysis patients.
At a mean dose of 1,080 mg/day, nicotinamide allowed 
control of P levels, also reducing LDL cholesterol and increas-
ing HDL cholesterol. Despite some concerns regarding side 
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effects (common side effects include diarrhea, drowsiness, 
dizziness, nausea, vomiting, headache, and flushing of 
the skin) determining possible patient noncompliance, 
nicotinamide mimics a noncalcium, nonaluminum phosphate 
binder with a significantly lower cost which is increasingly 
used in middle- to low-income countries.72 More rarely, nico-
tinamide can determine significant hepatotoxicity.73
Cost-effectiveness of calcium-free  
binders
The KDIGO guidelines recommend restricting the use of 
calcium-based binders in people with persistent or recurrent 
hypercalcemia or arterial calcification, or both. This recom-
mendation has been challenged by the Cochrane Review 
2011,74 suggesting that there are insufficient data to establish 
the comparative superiority of novel noncalcium binding 
agents over calcium-containing P binders for patient-level 
outcomes, such as all-cause mortality and cardiovascular 
endpoints in CKD. In this review, 60 controlled studies were 
identified, enrolling 7,631 participants comparing P binders to 
placebo or to other P binders. There was no significant reduc-
tion in all-cause mortality (ten studies; 3,079 participants) 
with sevelamer HCl compared to calcium-based agents. There 
was a significant reduction in P (16 studies; 3,126 partici-
pants) and parathyroid hormone (twelve studies; 2,551 
participants) levels, but a significant increase in the risk 
of hypercalcemia (twelve studies; 1,144 participants) with 
calcium salts compared to sevelamer HCl. There was a 
significant increase in the risk of adverse gastrointestinal 
events with sevelamer HCl compared to calcium salts (five 
studies; 498 participants). Compared with calcium-based 
agents, lanthanum significantly reduced-serum calcium (two 
studies; 122 participants), but not serum P levels. The effects 
of calcium acetate on biochemical endpoints were similar 
to those of calcium carbonate. Although methodologically 
flawless, this review cannot take into account specific hints 
derived by a careful analysis of published studies, as specified 
above in this article. In addition, the length of follow-up of the 
available studies might have been too short to show an effect 
of vascular calcifications on mortality and cardiovascular 
events. The issue of the dose of calcium-based binders is 
also not addressed by Navaneethan et al.74 This is particularly 
important, because vascular calcifications are more likely 
when a positive calcium balance, seen with the higher doses 
of calcium-based binders, occurs.
Calcium-free binders are effective and may offer addi-
tional advantages. The major issue against their widespread 
use is the markedly higher cost. Based on hospitalization data 
of the DCOR study, cost-effectiveness in sevelamer-treated 
versus calcium-treated patients was studied,75 evaluating 
Medicare total, inpatient, outpatient, skilled nursing facility, 
and other costs while incorporating sevelamer and calcium 
binder costs. Medicare costs were lower for sevelamer-treated 
than for calcium-treated participants, but after P binder costs 
were incorporated, costs trended lower for calcium-treated 
than for sevelamer-treated patients (differential −$25 per 
member per month, using wholesale acquisition cost). 
Whether calcium-free binders are cost-effective is still an 
open question, but – in our view – in case of doubts, the saf-
est option for the patient should be preferred until properly 
conducted studies demonstrate that high-dose calcium-based 
binders are harmless.
Combined treatment  
of phosphate binders, vitamin D,  
and/or calcimimetics
The combined treatment of calcium containing P binders 
and active vitamin D may induce an increase in calcium and 
P intestinal absorption, possibly leading to hypercalcemia 
and to more difficult control of P levels. Experimental stud-
ies have shown that paricalcitol appears to have selective 
action on the parathyroid vitamin D receptor, allowing it to 
exert beneficial effects on PTH secretion without elevating 
intestinal vitamin D receptor content and increasing the risk 
of hypercalcemia.76
The use of calcimimetics may be associated with a reduc-
tion in serum calcium (but, not necessarily, a reduction in 
calcium balance). After starting calcimimetic treatment 
for secondary hyperparathyroidism, an initial reduction 
of P levels might be due to P shift toward the bone, due 
to reduced PTH levels, rather than an effect on intestinal 
P transport.
Dietary management
Phosphorus enters the human body through food and 
beverages. The intestinal absorption of P occurs via a 
cotransport mechanism for active sodium/phosphate (Na/Pi) 
cotransporters. About 60% of the dietary P intake is absorbed 
as inorganic P, increasing up to 80% when concomitant high 
circulating levels of calcitriol exist.
Dietary P burden is a function of dietary food content and 
of food preparation. Phosphorus is introduced as a natural 
component of food as constituent of phosphoproteins, phos-
pholipids, adenosine triphosphate, adenosine diphosphate, 
deoxyribonucleic acid, ribonucleic acid, or as inorganic 
P salts. The latter may be found in foods, and also in food 
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additives that are added for commercial and technologi-
cal reasons during industrial food processing. In addition, 
P content of foods can be modified by homemade food 
preparation or cooking.
Protein-rich foods are the main source of dietary P in a 
free mixed diet, and the amount of P is directly proportional to 
protein content. There are equations that relate P and protein 
content of mixed diets: the most known is that of Boaz and 
Smetana,77 whose validity was confirmed in a cohort of 260 
Italian subjects (dietary P [mg] = 101.9 + 12.93 × dietary 
protein in g).78 However, this apparently ineluctable and 
constant relationship between the content of P and protein 
in a diet can be modified by education and information about 
food choice, processing, and cooking.
As far as the P content in major groups of natural foods 
is concerned, the highest amount of P is found in cheese 
(up to 700 mg/100 g); egg yolk (586 mg/100 g); meat or 
fish (170–290 mg/100 g); P content in legumes varies from 
300 to 590 mg/100 g; and in cereal grains from 120 to 
360 mg/100 g.79
Phosphorus is found in foods mainly as inorganic P, while 
a share of around 40% is contained in phosphoproteins and 
phospholipids.80 Net intestinal absorption of dietary P is 
60% as average. Bioavailability of P depends on the degree 
of digestibility of the food, the presence of compounds that 
can bind P inhibiting its absorption (eg, calcium, magnesium, 
aluminum), and/or the degree of vitamin D receptor activation 
in the gastrointestinal tract.
Phosphorus in foods of animal origin is more bioavailable 
than that found in foods of plant origin.81 The former is pres-
ent as inorganic salts or as part of organic compounds, which 
are cleaved by hydrolases in the intestinal tract releasing 
inorganic P, which is finally absorbed. The latter is largely in 
the form of phytate.82 Phytates are found mainly in cereals and 
legumes, where they are concentrated in the seeds and fibrous 
parts. This is the reason why they are abundant in whole grain 
products and virtually absent in refined products. In humans, 
the phytase enzyme is not expressed, so the degradation of 
phytate occurs by the intestinal flora or by nonenzymatic 
hydrolysis reactions.82 This results in reduced bioavailability 
of P of plant origin, remaining below 50%.
The positive relationship between P and protein content 
of a mixed diet represents a serious obstacle for the end stage 
renal disease patient. In fact, patients on dialysis must limit 
P intake, despite an increased demand of protein supply. In 
other words, dialysis patients should limit P intake without 
reducing their protein intake.79,83 The use of food composition 
tables that include data of P content per gram of protein may 
be of great benefit for both the patient and the dialysis staff, 
including the renal dietician.79,84 A typical example is the egg; 
the yolk contains most of the P (largely as phospholipids) 
with a small amount of protein, while the white part of the 
egg contains protein (3.7 g for one egg white) with a nearly 
absent P content. The egg white is, therefore, a natural source 
of protein of high biological value, almost free of P. So, the 
implementation of recipes involving the use or the addition 
of egg whites allows breaking the close positive relationship 
between protein and P, increasing the protein intake with a 
negligible supply of P.
Changes of phosphorus intake  
by industrial processing:  
food preservatives
Nowadays, food and beverages are consumed in places far 
away from where they were produced and/or a long period 
of time after their production. In any case, the product must 
maintain safety and taste characteristics. Hence, addition 
of preservatives is a technological need due to modern 
changes in the cycle of food production, distribution, and 
consumption.79
A food additive is any substance not normally consumed 
as a food in itself and not normally used as a characteristic 
ingredient of food, intentionally added to food for a tech-
nological need in the production, processing, preparation, 
packing, transport, or storage of foods. Food additives may 
become, by themselves or as derivatives, direct or indirect 
components of foods.
The European Community regulations provide the obliga-
tion to report the presence of P salts or polyphosphates on 
the food label, but their amounts are not required.
Consumers can find preservatives in the food label (in the 
list of ingredients) as full name or by the initial “E,” followed 
by a number that distinguishes the individual substances.79
Phosphorus is the main component of many additives 
(phosphoric acid, phosphates, and polyphosphates) in pro-
cessed foods. The P-containing additives are used as acidity 
regulators (E338–E343), and as emulsifiers and thickeners 
(E442, E450–E452, E544–E545). They are used by food 
industry processing for many purposes – to extend the conser-
vation, enhance color, enhance flavor, and retain moisture.79 
It is noteworthy that P in preservatives is present as inorganic 
salts and, thus, more easily absorbed in the intestine; its 
intestinal tract absorption rate approaches 100%.85
The load of P derived from inorganic P in food addi-
tives is disproportionately high, compared to naturally 
present P.79,80,85,86 In the USA, the P load from P-containing 
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preservatives increased significantly from an average of 
470 mg/day in 1990 to about 1,000 mg/day for a typical 
American diet in the year 2000.87 Foods containing additives 
are generally of lower quality and lower cost, compared to 
the fresh product. Hence, poorer segments of the population 
are at the greatest risk of an extra P load from additives, as 
suggested by a recent investigation.88
Changes of phosphorus intake  
by homemade processing: cooking
When considering the composition of natural and processed 
foods, nutrient content is generally referred to as the amount 
of the specific nutrient per 100 g of edible uncooked food. 
However, many foods are consumed after cooking, and this 
can induce a different actual P content of the food. Among 
the various methods of food cooking, boiling is able to reduce 
P content of the food, as well as the content of sodium, potas-
sium, calcium, etc, both in plant and in animal foods.
After prolonged soaking in water, a significant reduction 
in the P content occurs. The average reduction was 51% for 
vegetables; legumes, 48%; meat, 38%; flour, 70%; and cheese, 
19%.89 However, this type of procedure is poorly accepted by 
the patients, because it is time consuming and reduces the 
palatability and taste of various food preparations. Boiling is 
another effective method of P reduction. The loss of miner-
als is dependent on the amount of liquid used for boiling, as 
well as on time and degree of food shredding. Boiling meat 
allows a greater reduction of P than of protein content;79,90 
hence, this procedure is another way to break the positive 
relationship between dietary protein and P intake.90
Management of dietary phosphorus  
in clinical practice: need  
for education
In dialysis patients, diet alone is not able to control the 
P balance, because of the high protein requirement, but 
much can still be done to limit the dietary P load and to 
increase the efficacy of intestinal P binders. Indeed, even a 
high dose of P binder agents can block the absorption of up 
to 200–300 mg of dietary P, while an uncontrolled dietary P 
intake easily overcomes 1,000–1,500 mg per day. All these 
considerations appear quite obvious, but they are still largely 
overlooked. Unfortunately, a certain degree of nihilism exists 
with regard to dietary and nutritional counseling.91
Hence, the need for control and restriction of effective P 
intake becomes essential to reduce the net load of P to the 
body and to allow successful P-binding therapy. Education 
about the sources of dietary P92 and about the procedures 
and choices, allowing a reduction of effective P net intestinal 
absorption is, therefore, essential for a correct, safe, effective, 
and less-expensive control of P overload and of improved 
management of CKD–MBD.
Increased training and better information provided to 
nurses and to patients may facilitate more effective control 
of dietary P, reduction of costs, and improvement of the qual-
ity of care of hemodialysis patients.93,94 This is confirmed 
by reports showing that dietary counseling and educational 
interventions were effective in reducing P levels in CKD 
patients with hyperphosphatemia.95
In addition, an inadequate matching of P binder dosage 
and meal P loading may be a cause for failure of P balance 
control. Hence, an individual self-adjustment of P binders’ 
dose, in relation to estimated meal P content, can significantly 
improve the management of hyperphosphatemia.96
Conclusion
The limited availability of dialysis facilities, the lengthen-
ing of treatment times, and also the unwillingness of the 
patient all hamper the use of high-volume extracorporeal 
dialysis schedules, particularly due to logistic issues and to 
the higher costs involved. This, in turn, prevents an effective 
balance from being achieved between P input and P output 
in hemodialysis. Peritoneal dialysis represents a good 
alternative, although difficulties in P control are common 
in peritoneal dialysis patients as well. Hyperphosphatemia 
may be partially limited through use of HDF techniques. 
The application of daily dialysis and long-term dialysis 
protocols taking into account duration of treatment sessions 
is paramount in overcoming this challenge.
Using a three-times-a-week conventional dialysis regi-
men, the use of intestinal P binders is largely needed in well-
nourished dialysis patients, but they have limited capacity 
and efficacy if dietary P load is uncontrolled. Therefore, 
limitation of dietary P intake is needed as well.
In a free mixed diet, the P content is directly related to 
that of proteins. Thus, protein-rich foods, which are the main 
source of P, represent a huge problem for dialysis patients 
who need a high-protein diet. The share of intestinal absorp-
tion (about 60% as average) is negligible for plant P (in 
form of phytate), while it is the maximum (up to 100%) for 
P or polyphosphates contained in food additives. The latter 
represents a dangerous extra load of P, because they are hardly 
recognized by patients and widely used in modern nutrition, 
especially in low-cost food.
A simple and effective approach to reduce the load of 
dietary P without reducing that of proteins is to educate 
International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
203
Phosphate control in dialysis
patients avoiding foods high in P – such as cheese, egg 
yolk, nuts, and processed food  containing P additives. In 
addition, they should preferentially use boiling (that allows 
a decrease of sodium and potassium content, too) over other 
methods of cooking.
The collaboration of the dietitian is essential for nutri-
tional education, to help the patient in the choice of foods 
and to promote the effective adherence to dietary rules, all 
of which represent crucial aspects of an integrated approach 
to CKD–MBD.
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